LUCAR-B68
/ Legend Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
June 17, 2026
Universal BCMA-targeted LUCAR-B68 Cells in Patients With Relapsed/Refractory Multiple Myeloma
(clinicaltrials.gov)
- P1 | N=8 | Terminated | Sponsor: Second Affiliated Hospital of Xi'an Jiaotong University | N=34 ➔ 8 | Not yet recruiting ➔ Terminated; Achieved the proof of concept
Enrollment change • Trial termination • Hematological Malignancies • Multiple Myeloma • Oncology
August 12, 2022
Universal BCMA-targeted LUCAR-B68 Cells in Patients With Relapsed/Refractory Multiple Myeloma
(clinicaltrials.gov)
- P1 | N=34 | Not yet recruiting | Sponsor: Second Affiliated Hospital of Xi'an Jiaotong University
New P1 trial • Hematological Malignancies • Multiple Myeloma • Oncology
1 to 2
Of
2
Go to page
1